Baxter PE Ratio 2010-2023 | BAX
Current and historical p/e ratio for Baxter (BAX) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Baxter PE ratio as of April 26, 2024 is 14.86.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Baxter PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-04-26 | 40.13 | 7.69 | |
| 2023-12-31 | 38.39 | $5.22 | 7.35 |
| 2023-09-30 | 37.18 | $5.10 | 7.29 |
| 2023-06-30 | 44.56 | $-5.66 | 0.00 |
| 2023-03-31 | 39.39 | $-4.88 | 0.00 |
| 2022-12-31 | 49.15 | $-4.83 | 0.00 |
| 2022-09-30 | 51.65 | $-4.72 | 0.00 |
| 2022-06-30 | 61.28 | $2.00 | 30.64 |
| 2022-03-31 | 73.70 | $2.09 | 35.26 |
| 2021-12-31 | 81.32 | $2.53 | 32.14 |
| 2021-09-30 | 75.91 | $2.39 | 31.76 |
| 2021-06-30 | 75.72 | $2.19 | 34.57 |
| 2021-03-31 | 79.06 | $2.08 | 38.01 |
| 2020-12-31 | 74.98 | $2.14 | 35.04 |
| 2020-09-30 | 74.91 | $1.76 | 42.56 |
| 2020-06-30 | 79.97 | $1.78 | 44.93 |
| 2020-03-31 | 75.20 | $1.96 | 38.37 |
| 2019-12-31 | 77.25 | $1.98 | 39.02 |
| 2019-09-30 | 80.59 | $2.68 | 30.07 |
| 2019-06-30 | 75.27 | $2.97 | 25.34 |
| 2019-03-31 | 74.52 | $2.94 | 25.35 |
| 2018-12-31 | 60.17 | $2.15 | 27.99 |
| 2018-09-30 | 70.28 | $1.95 | 36.04 |
| 2018-06-30 | 67.14 | $1.43 | 46.95 |
| 2017-12-31 | 58.48 | $1.29 | 45.33 |
| 2017-09-30 | 56.63 | $1.86 | 30.45 |
| 2017-06-30 | 54.49 | $2.12 | 25.70 |
| 2017-03-31 | 46.55 | $1.88 | 24.76 |
| 2016-12-31 | 39.70 | $3.58 | 11.09 |
| 2018-03-31 | 58.98 | $9.26 | 6.37 |
| 2016-09-30 | 42.50 | $8.92 | 4.76 |
| 2016-06-30 | 40.26 | $8.68 | 4.64 |
| 2016-03-31 | 36.46 | $7.09 | 5.14 |
| 2015-12-31 | 33.77 | $1.75 | 19.30 |
| 2015-09-30 | 28.99 | $3.12 | 9.29 |
| 2015-06-30 | 33.26 | $3.98 | 8.36 |
| 2015-03-31 | 32.33 | $4.33 | 7.47 |
| 2014-12-31 | 34.33 | $4.14 | 8.29 |
| 2014-09-30 | 33.38 | $3.39 | 9.85 |
| 2014-06-30 | 33.39 | $3.60 | 9.28 |
| 2013-12-31 | 31.67 | $3.65 | 8.68 |
| 2013-09-30 | 29.69 | $3.95 | 7.52 |
| 2013-06-30 | 31.09 | $3.97 | 7.83 |
| 2013-03-31 | 32.37 | $3.96 | 8.17 |
| 2012-12-31 | 29.52 | $4.15 | 7.11 |
| 2014-03-31 | 33.74 | $4.30 | 7.85 |
| 2012-09-30 | 26.50 | $4.11 | 6.45 |
| 2012-06-30 | 23.19 | $4.06 | 5.71 |
| 2012-03-31 | 25.91 | $3.94 | 6.58 |
| 2011-12-31 | 21.32 | $3.88 | 5.50 |
| 2011-09-30 | 24.03 | $3.78 | 6.36 |
| 2011-06-30 | 25.41 | $3.78 | 6.72 |
| 2011-03-31 | 22.77 | $3.61 | 6.31 |
| 2010-12-31 | 21.31 | $3.49 | 6.11 |
| 2010-09-30 | 19.96 | $3.71 | 5.38 |
| 2010-06-30 | 16.89 | $3.57 | 4.73 |
| 2010-03-31 | 24.02 | $3.63 | 6.62 |
| 2009-12-31 | 24.10 | $3.60 | 6.69 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $20.379B | $14.813B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||